Characteristics and outcomes of adult patients with familial Mediterranean fever: comparison of patients with one versus two pathogenic exon 10 MEFV mutations.
{"title":"Characteristics and outcomes of adult patients with familial Mediterranean fever: comparison of patients with one versus two pathogenic exon 10 MEFV mutations.","authors":"Anaël Dumont, Hélène Vergneault, Samuel Ardois, Guilaine Boursier, Carole Lacout, Zohra Aknouche, Achille Aouba, Laurence Cuisset, Gilles Grateau, Léa Savey, Sophie Georgin-Lavialle","doi":"10.1016/j.jbspin.2025.105850","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>To describe the main features and outcomes of a large cohort of adult familial Mediterranean fever (FMF) patients with one pathogenic MEFV mutations and compare them to FMF patients displaying 2 pathogenic MEFV mutations.</p><p><strong>Methods: </strong>In a retrospective single-referential French center cohort of 581 patients with FMF, 178 FMF patients with one pathogenic mutation were retrieved and compared to 403 patients with 2 pathogenic MEFV mutations. The diagnosis of FMF was based on the Eurofever/PRINTO classification criteria for all patients, and they had all been sequenced for MEFV. Patients with M694V/E148Q genotype were also compared to M694V/WT patients.</p><p><strong>Results: </strong>Compared to FMF patients with 2 pathogenic MEFV mutations, patients with one pathogenic mutation showed significantly higher age at diagnosis and at disease onset (25 vs 10 years and 12 vs 5 years, p<0.001, respectively), higher personal history (21% vs 5%, p<0.001) or familial history (13% vs 5%, p=0.001) of recurrent aphthous stomatitis (RAS) and higher body mass index (BMI) (24 vs 23 kg/m², p<0.05). Conversely, patients with one mutation showed no AA amyloidosis (0 vs 6%, p=0.001) and lower colchicine dosage (p<0.001) than patients with two pathogenic MEFV mutations. These differences remained significant after adjustments for age at disease onset (beginning in childhood or adulthood). No clinical difference was found between patients with M694V/E148Q and M694V/WT.</p><p><strong>Conclusion: </strong>Adult FMF patients with a single pathogenic MEFV mutation display specific clinical features as well as different evolution compared to patients with 2 pathogenic MEFV mutations.</p>","PeriodicalId":54902,"journal":{"name":"Joint Bone Spine","volume":" ","pages":"105850"},"PeriodicalIF":3.8000,"publicationDate":"2025-01-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Joint Bone Spine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.jbspin.2025.105850","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"RHEUMATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Objective: To describe the main features and outcomes of a large cohort of adult familial Mediterranean fever (FMF) patients with one pathogenic MEFV mutations and compare them to FMF patients displaying 2 pathogenic MEFV mutations.
Methods: In a retrospective single-referential French center cohort of 581 patients with FMF, 178 FMF patients with one pathogenic mutation were retrieved and compared to 403 patients with 2 pathogenic MEFV mutations. The diagnosis of FMF was based on the Eurofever/PRINTO classification criteria for all patients, and they had all been sequenced for MEFV. Patients with M694V/E148Q genotype were also compared to M694V/WT patients.
Results: Compared to FMF patients with 2 pathogenic MEFV mutations, patients with one pathogenic mutation showed significantly higher age at diagnosis and at disease onset (25 vs 10 years and 12 vs 5 years, p<0.001, respectively), higher personal history (21% vs 5%, p<0.001) or familial history (13% vs 5%, p=0.001) of recurrent aphthous stomatitis (RAS) and higher body mass index (BMI) (24 vs 23 kg/m², p<0.05). Conversely, patients with one mutation showed no AA amyloidosis (0 vs 6%, p=0.001) and lower colchicine dosage (p<0.001) than patients with two pathogenic MEFV mutations. These differences remained significant after adjustments for age at disease onset (beginning in childhood or adulthood). No clinical difference was found between patients with M694V/E148Q and M694V/WT.
Conclusion: Adult FMF patients with a single pathogenic MEFV mutation display specific clinical features as well as different evolution compared to patients with 2 pathogenic MEFV mutations.
期刊介绍:
Bimonthly e-only international journal, Joint Bone Spine publishes in English original research articles and all the latest advances that deal with disorders affecting the joints, bones, and spine and, more generally, the entire field of rheumatology.
All submitted manuscripts to the journal are subjected to rigorous peer review by international experts: under no circumstances does the journal guarantee publication before the editorial board makes its final decision. (Surgical techniques and work focusing specifically on orthopedic surgery are not within the scope of the journal.)Joint Bone Spine is indexed in the main international databases and is accessible worldwide through the ScienceDirect and ClinicalKey platforms.